Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 23, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

6.7K

An in vitro osteosarcoma 3D microtissue model for drug development.

Markus Rimann1, Sandra Laternser1, Ana Gvozdenovic2

  • 1Institute of Chemistry and Biological Chemistry (ICBC), Zurich University of Applied Sciences, Waedenswil, Switzerland.

Journal of Biotechnology
|September 20, 2014
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value operating system: a practical framework to measure outcomes-per-cost at the episode level.

BMJ open quality·2026
Same author

Directed evolution of compact RNA-guided nucleases for enhanced activity in mammalian cells.

Genome biology·2026
Same author

Integration and validation of complementary ex vivo assays for functional precision oncology.

NPJ precision oncology·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026
Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026

This study developed a 3D microtissue model for osteosarcoma (OS) drug development. The 3D model better reflects tumor heterogeneity and drug resistance compared to 2D models, aiding personalized medicine approaches.

Area of Science:

  • Oncology
  • Biotechnology
  • Drug Development

Background:

  • Osteosarcoma (OS) is a primary bone cancer in children and adolescents with poor survival rates for metastatic disease.
  • Current therapies involve surgery and chemotherapy, but drug resistance remains a significant challenge.
  • There is a need for more biologically relevant models to improve OS drug development.

Purpose of the Study:

  • To develop a 3D microtissue model of osteosarcoma (OS) that accurately reflects tumor heterogeneity.
  • To assess the suitability of this 3D model for evaluating drug efficacy in OS.
  • To compare drug responses in 3D microtissues versus traditional 2D cell cultures.

Main Methods:

  • Osteosarcoma (OS) cell lines (SaOS-2, HOS, MG-63) and patient-derived cells were used to create 3D microtissues via the hanging drop method.
Keywords:
3D tissue modelAlternative to animal testingDrug developmentOsteosarcomaPersonalised medicine

More Related Videos

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.6K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

6.7K
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.6K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.0K
  • Histological characterization (H/E, Ki-67, TUNEL) was performed to assess microtissue structure and cellular processes.
  • Microtissues were treated with various chemotherapy drugs (doxorubicin, cisplatin, etc.), and cell viability was measured using a luminescent assay.

    • Main Results:

    • The 3D microtissues exhibited histological heterogeneity, mirroring OS characteristics.
    • Drug efficacy testing showed significantly higher IC50 values in 3D cultures compared to 2D cultures for most tested drugs, indicating increased drug resistance.
    • Doxorubicin demonstrated differential efficacy, being ineffective in 2D chondroblastic cultures but showing a measurable IC50 in 3D microtissues.

    Conclusions:

    • The developed 3D OS microtissue model effectively recapitulates tumor heterogeneity.
    • This 3D model is a promising tool for preclinical drug screening and development in osteosarcoma.
    • The findings suggest that 3D models are crucial for understanding drug resistance and advancing personalized medicine for OS patients.